Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP632 | DOI: 10.1530/endoabs.99.EP632

1General Hospital Vukovar, Department of Internal Medicine, Vukovar, Croatia; 2Faculty of Medicine Osijek, Osijek, Croatia; 3Clinical Hospital Center Osijek, Department of Endocrinology, Osijek, Croatia; 4General Hospital Virovitica, Department of Internal Medicine, Virovitica, Croatia


Introduction: Pheochromocytomas, rare neuroendocrine tumors originating from adrenal medulla chromaffin cells, excessively secrete catecholamines, manifesting diverse symptoms. With an incidence of 2-9 per million inhabitants, these tumors pose diagnostic challenges due to their varied clinical presentation.

Case Description: We present five patients diagnosed with pheochromocytoma at the Clinical Hospital Center Osijek. The incidentaloma of the adrenal gland was discovered while diagnosing unrelated conditions, and none of the patients displayed typical pheochromocytoma symptoms. While one patient reported abdominal pain, others remained asymptomatic. CT was performed, and all patients exhibited significantly elevated normetanephrine levels in serum and urine, with only one showing marginally elevated metanephrine in urine. Patients’ characteristics are shown in Table 1.

Table 1. Clinical Profile Summary
Patient 1 2 3 4 5
Age (years) 34 76 67 67 57
Sex (male/female) male female male male female
Body mass index (kg/m2;) 21.5 34.1 26.6 25.8 28.4
Prior cardiovascular disease - - yes - -
Hypertension - yes yes - yes
Number of antihypertensives 0 2 1 0 1
Beta - blocker - - yes - yes
Positive family history - - - - -
CT* characteristics Side, size (cm), native density (**HU), absolute wash - out/relative wash - out (%)) left, 11x8.8, 30, 60/40 left, 3.8x4.6, 32 left, 3.5x3.1, 35, 71/56 right, 1.6x1.4, 30, 38/54 left, 3.8x3.4, 20, 59/69
Plasma metanephrine (pmol/l), reference range 0.22 (0.01-0.3) - 0.34 (0.05-0.36) 0.27 (0.05-0.36) 0.29 (0.05-0.38)
Plasma normetanephrine (pmol/l), reference range 0.80 (0.13-0.62) - 3.87 (0.14-1.05) 1.68 (0.14-1.05) 3.20 (0.14-0.75)
Urinary metanephrine (umol/dU), reference range 0.20 (<0.27) 0.18 (<0.17) 0.19 (<0.27) 0.12 (<0.27) 0.86 (<1.62)
Urinary normetanephrine (umol/dU), reference range 0.48 (<0.24) 3.96 (<0.19) 0.95 (<0.24) 0.38 (<0.24) 5.34 (<2.13)
Tumor type pheochromocytoma/paraganglioma pheochromocytoma pheochromocytoma pheochromocytoma pheochromo cytoma
Size of tumor (cm) - PHD 12x11.5 5x3.8 4.2x2.7 1x1.2 3x2.5
AJCC*** staging pT2 pT2 pT1 pT1 pT1
PASS score**** 7/20 4/20 1/20 - 0/20
Ki-67 (%) 1 - 3 1 <1 < 1 2
Treatment surgery surgery surgery surgery surgery
Follow - up complete response complete response complete response complete response complete response
*CT: computed tomography; **HU: Hounsfield Units; ***AJCC: American Joint Committee on Cancer Staging for Pheochromocytoma, ****PASS Score: Pheochromocytoma of the Adrenal Gland Scaled Score

Conclusion: Pheochromocytoma, lacking specific symptoms, often evades recognition. If there is a clinical suspicion or imaging finding of incidentaloma of the adrenal gland, biochemical testing for pheochromocytoma is crucial.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.